132 related articles for article (PubMed ID: 8840431)
1. Effectiveness of an adriamycin immunoconjugate that recognizes the C-erbB-2 product on breast cancer cell lines.
Jinno H; Ueda M; Enomoto K; Ikeda T; Kyriakos P; Kitajima M
Surg Today; 1996; 26(7):501-7. PubMed ID: 8840431
[TBL] [Abstract][Full Text] [Related]
2. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2.
Wright M; Grim J; Deshane J; Kim M; Strong TV; Siegal GP; Curiel DT
Gene Ther; 1997 Apr; 4(4):317-22. PubMed ID: 9176517
[TBL] [Abstract][Full Text] [Related]
3. Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker.
Greenfield RS; Kaneko T; Daues A; Edson MA; Fitzgerald KA; Olech LJ; Grattan JA; Spitalny GL; Braslawsky GR
Cancer Res; 1990 Oct; 50(20):6600-7. PubMed ID: 2208122
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.
Eloy JO; Petrilli R; Brueggemeier RW; Marchetti JM; Lee RJ
Anticancer Agents Med Chem; 2017; 17(1):48-56. PubMed ID: 27225450
[TBL] [Abstract][Full Text] [Related]
5. Selective cytotoxicity of adriamycin immunoconjugate of monoclonal antibody MSN-1 to endometrial adenocarcinoma in vitro and in vivo.
Kaneta Y; Tsukazaki K; Kubushiro K; Sakayori M; Ueda M; Nozawa S
Oncol Rep; 2000; 7(5):1099-106. PubMed ID: 10948346
[TBL] [Abstract][Full Text] [Related]
6. [The antitumor effect of adriamycin conjugated with monoclonal antibody against gastric cancer in vitro and in vivo].
Zhang YT; Wang NQ; Li N; Liu T; Dong ZW
Yao Xue Xue Bao; 1992; 27(5):325-30. PubMed ID: 1442051
[TBL] [Abstract][Full Text] [Related]
7. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates.
Savellano MD; Pogue BW; Hoopes PJ; Vitetta ES; Paulsen KD
Cancer Res; 2005 Jul; 65(14):6371-9. PubMed ID: 16024640
[TBL] [Abstract][Full Text] [Related]
8. Immunoselective cell growth inhibition by antibody-adriamycin conjugates targeting c-erbB-2 product on human cancer cells.
Suzuki S; Tanaka M; Masuko T; Hashimoto Y
Biol Pharm Bull; 1995 Sep; 18(9):1279-82. PubMed ID: 8845823
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor-dependent cytotoxic effect by an EGF-ribonuclease conjugate on human cancer cell lines--a trial for less immunogenic chimeric toxin.
Jinno H; Ueda M; Ozawa S; Kikuchi K; Ikeda T; Enomoto K; Kitajima M
Cancer Chemother Pharmacol; 1996; 38(4):303-8. PubMed ID: 8674151
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of breast cancer cells overexpressing HER2/neu by 213Bi-Herceptin radioimmunoconjugate.
Zhang DY; Li Y; Rizvi SM; Qu C; Kearsley J; Allen BJ
Cancer Lett; 2005 Feb; 218(2):181-90. PubMed ID: 15670895
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing.
Braslawsky GR; Edson MA; Pearce W; Kaneko T; Greenfield RS
Cancer Res; 1990 Oct; 50(20):6608-14. PubMed ID: 2208123
[TBL] [Abstract][Full Text] [Related]
12. Specific targeting of HER2-positive human breast carcinoma SK-BR-3 cells by amygdaline-Z
Moradipoodeh B; Jamalan M; Zeinali M; Fereidoonnezhad M; Mohammadzadeh G
Mol Biol Rep; 2020 Sep; 47(9):7139-7151. PubMed ID: 32929653
[TBL] [Abstract][Full Text] [Related]
13. A Novel Affibody-Auristatin E Conjugate With a Potent and Selective Activity Against HER2+ Cell Lines.
Sochaj-Gregorczyk AM; Serwotka-Suszczak AM; Otlewski J
J Immunother; 2016; 39(6):223-32. PubMed ID: 27227324
[TBL] [Abstract][Full Text] [Related]
14. [Antitumor effect of adriamycin conjugated with downsized anti-endoglin monclonal antibody].
Li L; Huang FY; Huang YH; Zhou SL; Guo JL; Zhao HG; Tan GH; Wang H
Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 May; 43(3):340-3. PubMed ID: 22812233
[TBL] [Abstract][Full Text] [Related]
15. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
16. [Antitumor effect of the novel immunoconjugate composed of pingyangmycin and anti-type IV collagenase monoclonal antibody].
Dai Y; Liu XJ; Zhen YS
Yao Xue Xue Bao; 2006 Jan; 41(1):41-6. PubMed ID: 16683526
[TBL] [Abstract][Full Text] [Related]
17. [Targeting therapy with adriamycin-monoclonal antibody (HAb18) conjugate in nude mice with human hepatocellular carcinoma xenografts].
Sui Y
Zhonghua Yi Xue Za Zhi; 1992 Jul; 72(7):397-400, 445. PubMed ID: 1330227
[TBL] [Abstract][Full Text] [Related]
18. Investigation of an antitumor drug-delivery system based on anti-HER2 antibody-conjugated BSA nanoparticles.
Zhang N; Zhang J; Wang P; Liu X; Huo P; Xu Y; Chen W; Xu H; Tian Q
Anticancer Drugs; 2018 Apr; 29(4):307-322. PubMed ID: 29381491
[TBL] [Abstract][Full Text] [Related]
19. Immunofluorescent localization of C-erbB-2 oncoprotein in breast cancer: a preliminary study.
Meenakshi A; Kumar RS; Siva Kumar N; Ganesh V
Hum Antibodies; 2002; 11(3):73-7. PubMed ID: 12454367
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, characterization, and biological verification of anti-HER2 indocyanine green-doxorubicin-loaded polyethyleneimine-coated perfluorocarbon double nanoemulsions for targeted photochemotherapy of breast cancer cells.
Lee YH; Ma YT
J Nanobiotechnology; 2017 May; 15(1):41. PubMed ID: 28521752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
